Disease/Infection News

RSS

Abstract on ACH-1625 accepted as late breaking poster presentation at The Liver Meeting 2010

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that its abstract titled "ACH-1625 Demonstrates Sustained Viral Suppression in Presence of Uncommon Drug Resistant HCV Variants: Pharmacokinetic, Pharmacodynamic and Clinical Virology Analysis of Phase I Study" has been accepted as a late breaking poster presentation at the 61st Annual Meeting of the American Association for the Study of Liver Disease The Liver Meeting 2010 being held October 29-November 2, 2010 in Boston.

15 Sep 2010

Actress joins UTHealth to establish 'John Ritter Research Program in Aortic and Vascular Diseases'

Actress, writer and aortic health advocate Amy Yasbeck has joined with The University of Texas Health Science Center at Houston (UTHealth) to establish the John Ritter Research Program in Aortic and Vascular Diseases (JRRP) to combat the devastating disease that took the life of her husband, legendary comic actor John Ritter.

15 Sep 2010

AAPCHO launches campaign to raise chronic hepatitis B awareness

The U.S. Department of Health and Human Services' Office of Minority Health, the Hepatitis B Foundation and the Association of Asian Pacific Community Health Organizations (AAPCHO) today launched a new campaign to raise awareness of the epidemic of chronic hepatitis B among Americans of Asian and Pacific Islander heritage.

15 Sep 2010

ITS commences treatment in synthetic universal influenza vaccine Phase I trial

Immune Targeting Systems (ITS) Limited, one of the leading developers of synthetic vaccines for mutating viruses, today announced the first patient has been treated in its Phase-I trial with its synthetic universal influenza vaccine (FP-01). Commencement of trials follows receipt of UK Regulatory Authority (MHRA) approval. Over the same period the company brought in £500,000 new investment from Esperante Ventures (UK).

15 Sep 2010

Scientist to develop antibiotics for drug-resistant superbugs

Antibiotics can work miracles, knocking out common infections like bronchitis and tonsillitis. But according to the Center for Disease Control, each year 90,000 people in the U.S. die of drug resistant "superbugs" bacteria like Staphylococcus aureus (MRSA), a deadly form of staph infection resistant to normal antibiotics. Although hospital patients are particularly susceptible as a result of open wounds and weakened immune systems, the bacteria can infect anyone. Dr. Micha Fridman of Tel Aviv University's Department of Chemistry is now developing the next generation of antibiotics designed to overcome this kind of bacteria. And the key, he says, is in the bacteria itself.

15 Sep 2010

MVI agrees to provide fund for evaluating Inovio's malaria DNA vaccine candidate in non-human primates

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the PATH Malaria Vaccine Initiative (MVI) has agreed to provide follow-on funding to continue evaluation and development of Inovio's malaria DNA vaccine candidate in non-human primates.

15 Sep 2010

Optimer Pharmaceuticals to present fidaxomicin Phase 3 clinical trial data at ICAAC Conference

Optimer Pharmaceuticals, Inc. announced the presentation of new data from its North American and European fidaxomicin Phase 3 clinical trials in patients with Clostridium difficile infection (CDI) at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston.

15 Sep 2010

RAB-1 monoclonal antibody study shows positive result for rabies

With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.

15 Sep 2010

Unsuccessful gum-disease treatment linked to preterm birth

A collaboration led by a periodontal researcher from the University of Pennsylvania School of Dental Medicine has found a possible link between the success of gum-disease treatment and the likelihood of giving birth prematurely, according to a study published in the journal BJOG: An International Journal of Obstetrics and Gynaecology.

15 Sep 2010

NIH grants award to expand Human Microbiome Project

The National Institutes of Health has awarded a three-year, $1.1 million grant to a team of scientists at the University of Chicago and Argonne National Laboratory to develop a technology for studying the link between human health and disease and the microorganisms that reside in or on the human body.

15 Sep 2010

Pregnant women should get immunized against flu

There will be only one flu shot needed this year and pregnant women should make sure they're at the front of the line to get it.

15 Sep 2010

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

15 Sep 2010

Arizona State University receives grant to protect warfighters from infectious diseases

Scientists at the Biodesign Institute at Arizona State University have received a 2-year, $5.3 million grant from the Defense Advanced Research Projects Agency (DARPA) to protect warfighters in the event of exposure to infectious diseases during deployment.

15 Sep 2010

CytoGenix reports positive results of CYDBA507 avian influenza vaccine candidate

CytoGenix reports positive results of an animal study where mice were immunized with CYDBA507, CytoGenix avian influenza vaccine candidate, protected against lethal challenge with avian influenza virus.

15 Sep 2010

Dana-Farber doctor hosts live program on Twitter to discuss head and neck cancers

The recent news that Michael Douglas has been diagnosed with stage 4 throat cancer has raised public awareness of head and neck cancer. What causes throat cancer and what are the symptoms? Are there ways to prevent or reduce the risk of throat cancer? How is the human papillomavirus (HPV) related to oral cancer?

14 Sep 2010

Experts to announce new findings on Malaria control

Leading malaria experts, officials and advocates to announce new findings detailed in "Saving Lives with Malaria Control: Counting Down to the Millennium Development Goals," a report published as part of the Roll Back Malaria Partnership's Progress & Impact Series.

14 Sep 2010

AIDS activists protest to decry Obama administration's dismal record on AIDS

52 AIDS activists from the groups Housing Works, AIDS Action in Mississippi (AAIM) and AIDS Healthcare Foundation (AHF) interrupted a speech by Health and Human Services Secretary Kathleen Sebelius with a spirited protest to decry the Obama administration's dismal record on AIDS during an appearance by the Secretary at the United States Conference on AIDS (USCA) on Monday in Orlando.

14 Sep 2010

More adults washing hands in public restrooms

In the latest observational study sponsored by the American Society for Microbiology and the American Cleaning Institute- (formerly The Soap and Detergent Association), 85% of adults washed their hands in public restrooms, compared with 77% in 2007. The 85% total was actually the highest observed since these studies began in 1996. The results were announced at the Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting sponsored by the American Society for Microbiology.

14 Sep 2010

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences, Inc. today announced Phase II clinical trial results showing that its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks, exhibiting antiretroviral activity comparable to that of Atripla(efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

14 Sep 2010

Gladstone Institute elects for 2010 recipient of Avant-Garde Award for HIV/AIDS Research

The National Institute on Drug Abuse, part of the National Institutes of Health, announced today that Dr. Eric M. Verdin of the J. David Gladstone Institutes in San Francisco, Calif., has been selected as the 2010 recipient of the NIDA Avant-Garde Award for HIV/AIDS Research for his proposal to study the mechanisms of latent HIV infection.

14 Sep 2010

Disease/Infection News

Abstract on ACH-1625 accepted as late breaking poster presentation at The Liver Meeting 2010

Actress joins UTHealth to establish 'John Ritter Research Program in Aortic and Vascular Diseases'

AAPCHO launches campaign to raise chronic hepatitis B awareness

ITS commences treatment in synthetic universal influenza vaccine Phase I trial

Scientist to develop antibiotics for drug-resistant superbugs

MVI agrees to provide fund for evaluating Inovio's malaria DNA vaccine candidate in non-human primates

Optimer Pharmaceuticals to present fidaxomicin Phase 3 clinical trial data at ICAAC Conference

RAB-1 monoclonal antibody study shows positive result for rabies

Unsuccessful gum-disease treatment linked to preterm birth

NIH grants award to expand Human Microbiome Project

Pregnant women should get immunized against flu

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Arizona State University receives grant to protect warfighters from infectious diseases

CytoGenix reports positive results of CYDBA507 avian influenza vaccine candidate

Dana-Farber doctor hosts live program on Twitter to discuss head and neck cancers

Experts to announce new findings on Malaria control

AIDS activists protest to decry Obama administration's dismal record on AIDS

More adults washing hands in public restrooms

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gladstone Institute elects for 2010 recipient of Avant-Garde Award for HIV/AIDS Research

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News